Mtorc modulators and uses thereof
AssigneeAeovian Pharmaceuticals, Inc.
InventorsStelios T. TZANNIS, Ian J. MASSEY, Alexandre FROIDBISE, Guillaume EPPE
Life of this patent
Estimating the term…
Abstract
Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
Claims21
-22. (canceled)
A method of treating tuberous sclerosis complex (TSC) in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from:
- or a pharmaceutically acceptable salt thereof.
A method of treating tuberous sclerosis complex (TSC) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound selected from:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.